Table 3 –
Risk of deterioration of HRQoL according to recurrence statusa
| Any recurrence | Local recurrence only | Distant recurrence | |
|---|---|---|---|
| EORTC QLQ-C30 (N = 645) | |||
| Recurrence, n (%) | 210 (32.6) | 74 (11.5) | 136 (21.1) |
| Adjusted HR (95% CI) for recurrence vs no recurrence | |||
| Global health status/QoL | 3.4 (2.3–5.3) | 3.0 (1.6–5.6) | 3.8 (2.3–6.3) |
| Physical functioning | 3.9 (2.6–6.0) | 1.6 (0.7–3.7) | 5.8 (3.7–9.1) |
| Role functioning | 2.8 (1.9–4.2) | 1.7 (0.9–3.5) | 3.6 (2.3–5.7) |
| Fatigue | 1.6 (1.1–2.5) | 1.2 (0.6–2.0) | 2.0 (1.2–3.3) |
| EQ-5D-3L (N = 648) | |||
| Recurrence, n (%) | 212 (32.7) | 75 (11.6) | 137 (21.1) |
| Adjusted HR (95% CI) for recurrence vs no recurrence | |||
| VAS | 1.9 (1.2–3.0) | 1.3 (0.6–2.8) | 2.4 (1.4–4.1) |
CI = confidence interval; EORTC QLQ-C30 = European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; HR = hazard ratio; HRQoL = health-related quality of life; VAS = visual analog scale.
a
Hazard ratios were calculated with no recurrence as the reference category.